Affimed Announces Acceptance Of An Abstract On Preclinical Data Of Its Innate Cell Engager AFM28 At The EHA 2024 Congress
Portfolio Pulse from Benzinga Newsdesk
Affimed N.V. announced the acceptance of an abstract on preclinical data of its CD16A/CD123-targeting innate cell engager, AFM28, for presentation at the EHA 2024 Congress. The data demonstrates AFM28's effectiveness in controlling tumor growth and reducing leukemic blasts and stem cells in AML models.
May 14, 2024 | 2:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Affimed's announcement of the acceptance of an abstract for the EHA 2024 Congress highlights promising preclinical data for AFM28, potentially boosting investor confidence in its AML treatment pipeline.
The acceptance of the abstract for a prestigious congress like EHA suggests strong scientific interest and validation of AFM28's potential in AML treatment. This could lead to increased investor confidence and potentially positive impacts on Affimed's stock price in the short term, as it underscores the company's progress in developing innovative cancer treatments.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100